Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Detection of bladder cancer using proteomic profiling of urine sediments.

Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B.

PLoS One. 2012;7(8):e42452. doi: 10.1371/journal.pone.0042452. Epub 2012 Aug 3.

2.

Multiplex protein signature for the detection of bladder cancer in voided urine samples.

Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S.

J Urol. 2013 Dec;190(6):2257-62. doi: 10.1016/j.juro.2013.06.011. Epub 2013 Jun 11.

3.
4.

Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma.

Mengual L, Burset M, Ribal MJ, Ars E, Marín-Aguilera M, Fernández M, Ingelmo-Torres M, Villavicencio H, Alcaraz A.

Clin Cancer Res. 2010 May 1;16(9):2624-33. doi: 10.1158/1078-0432.CCR-09-3373. Epub 2010 Apr 20.

5.

Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.

Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr GL Jr.

Am J Pathol. 2001 Apr;158(4):1491-502.

6.

Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.

Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC, Huang MM, Tong JH, Song EJ, Chang DC, Hsu CD, To KF, Shen CH, Chan MW.

BMC Med Genomics. 2011 May 20;4:45. doi: 10.1186/1755-8794-4-45.

7.

Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer.

Golijanin D, Shapiro A, Pode D.

J Urol. 2000 Dec;164(6):1922-5.

PMID:
11061882
8.

Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.

Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, Hermanns T, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1798-806. doi: 10.1158/1055-9965.EPI-09-0099. Epub 2009 May 19. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):629-30.

9.

Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.

Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, To KF.

Int J Cancer. 2003 May 1;104(5):611-6.

10.

ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients.

Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K.

Eur Urol. 2005 Jun;47(6):885-93; discussion 893-4. Epub 2005 Mar 11.

PMID:
15925088
11.

Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.

Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP.

BMC Cancer. 2011 Jun 10;11:234. doi: 10.1186/1471-2407-11-234.

12.

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B.

J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11. doi: 10.1093/jnci/djn304. Epub 2008 Sep 23. Erratum in: J Natl Cancer Inst. 2008 Dec 3;100(23):1740.

13.

Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity.

Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC.

Cancer. 1998 Feb 15;82(4):708-14.

PMID:
9477104
14.

Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.

Smrkolj T, Mihelič M, Sedlar A, Sterle I, Osredkar J, Sedmak B.

Clin Chem Lab Med. 2011 Feb;49(2):311-6. doi: 10.1515/CCLM.2011.038. Epub 2010 Dec 1.

PMID:
21118051
15.

[Tree analysis pattern of mass spectral urine profiles in differential diagnosis of bladder transitional cell carcinoma].

Wu DL, Zhang YF, Guan M, Liu WW, Xu YM, Jin SB, Zhang J, Jin CR, Lü Y.

Zhonghua Zhong Liu Za Zhi. 2007 Apr;29(4):274-7. Chinese.

PMID:
17760254
16.

Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.

Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF.

Clin Cancer Res. 2002 Feb;8(2):464-70.

17.

Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.

Retz M, Lehmann J, Amann E, Wullich B, Röder C, Stöckle M.

J Urol. 2003 Jan;169(1):86-9.

PMID:
12478110
18.

Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.

Andersson E, Steven K, Guldberg P.

PLoS One. 2014 Apr 14;9(4):e94023. doi: 10.1371/journal.pone.0094023. eCollection 2014.

19.

Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients.

Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y.

Eur Urol. 2005 Apr;47(4):456-62. Epub 2004 Nov 11.

PMID:
15774241
20.

Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.

Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E.

Urology. 2004 Feb;63(2):398-401.

PMID:
14972510

Supplemental Content

Support Center